Moving beyond response criteria: new measures of success in the treatment of sarcomas.
There is an urgent need to develop new therapies for soft tissue sarcomas. Traditional cytotoxic therapies, such as doxorubicin and ifosfamide, have been the standard approach to this disease. However, newer paradigms are emerging that are less toxic while targeting dysregulated pathways, tumor hypoxia, and genetic translocations. These newer therapies require different measures of activity as standard response criteria may inaccurately measure their effectiveness. Serious consideration of select endpoints and measures of tumor response are crucial to make significant strides in the treatment of sarcomas. Current studies on soft tissue sarcomas are slowly abandoning response rates while employing progression-free survival and time to progression as improved endpoints. With time and data, our understanding of the relative activity of these agents will grow and lead to improved benefits for our patients.
Sarcoma Oncology Center, Santa Monica, CA 90403, USA. ahendifar@gmail.com
Andrew E
AE
Hendifar
Elke
E
Ahlmann
Daniel C
DC
Allison
James
J
Hu
Lawrence
L
Menendez
Sant P
SP
Chawla
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D011379:Prognosis; D012509:Sarcoma / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
D000970:Antineoplastic Agents